Agilent Technologies, Inc. (A) Earns “Overweight” Rating from Morgan Stanley
Agilent Technologies, Inc. (NYSE:A)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Morgan Stanley in a note issued to investors on Monday, MarketBeat Ratings reports.
Several other brokerages also recently issued reports on A. Deutsche Bank AG reaffirmed a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a research report on Thursday, June 22nd. BidaskClub downgraded shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. BTIG Research increased their price objective on shares of Agilent Technologies from $57.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. Robert W. Baird increased their price objective on shares of Agilent Technologies from $57.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, May 24th. Finally, Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research report on Tuesday, May 16th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $59.62.
Agilent Technologies (NYSE:A) opened at 59.80 on Monday. The stock has a 50 day moving average of $58.94 and a 200 day moving average of $52.92. Agilent Technologies has a 1-year low of $42.92 and a 1-year high of $61.15. The stock has a market cap of $19.22 billion, a price-to-earnings ratio of 33.61 and a beta of 1.31.
Agilent Technologies (NYSE:A) last posted its earnings results on Monday, May 22nd. The medical research company reported $0.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.10. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The firm had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the company earned $0.44 EPS. The company’s revenue was up 8.1% on a year-over-year basis. Equities analysts expect that Agilent Technologies will post $2.23 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd will be given a $0.132 dividend. This represents a $0.53 annualized dividend and a yield of 0.88%. The ex-dividend date is Thursday, June 29th. Agilent Technologies’s dividend payout ratio is presently 29.78%.
ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/10/agilent-technologies-nysea-overweight-rating-reaffirmed-at-morgan-stanley.html.
In other news, insider Patrick Kaltenbach sold 2,000 shares of the firm’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $54.50, for a total transaction of $109,000.00. Following the transaction, the insider now directly owns 42,132 shares of the company’s stock, valued at $2,296,194. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 50,000 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $59.86, for a total value of $2,993,000.00. The disclosure for this sale can be found here. Insiders sold 147,119 shares of company stock worth $8,626,419 over the last ninety days.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Agilent Technologies by 1,946.9% in the first quarter. BlackRock Inc. now owns 23,119,219 shares of the medical research company’s stock worth $1,222,310,000 after buying an additional 21,989,739 shares during the last quarter. FMR LLC raised its position in Agilent Technologies by 3.9% in the first quarter. FMR LLC now owns 21,588,407 shares of the medical research company’s stock worth $1,141,379,000 after buying an additional 803,993 shares during the last quarter. Vanguard Group Inc. raised its position in Agilent Technologies by 0.4% in the first quarter. Vanguard Group Inc. now owns 21,455,971 shares of the medical research company’s stock worth $1,134,378,000 after buying an additional 75,886 shares during the last quarter. State Street Corp raised its position in Agilent Technologies by 1.0% in the first quarter. State Street Corp now owns 14,457,425 shares of the medical research company’s stock worth $764,348,000 after buying an additional 147,518 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Agilent Technologies by 31.4% in the first quarter. JPMorgan Chase & Co. now owns 8,366,511 shares of the medical research company’s stock worth $442,338,000 after buying an additional 1,999,376 shares during the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.